Stock Screener App

Frei -

Installieren

2.24

0.88% -0.02

Lexicon Pharmaceuticals Inc (LXRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt LXRX? Forum Prognose Aktiensplit

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st

Lexicon (LXRX) Levels: Slides 0.41% to $2.41 in the Current Update; Technical Setup - vinanet.vn

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets (NASDAQ:LXRX) - Seeking Alpha

Lexicon Pharmaceuticals Inc (LXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart - ChartMill

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat

LEXICON PHARMACEUTICALS, INC. SEC Filing (Aug 17, 2026) - Stock Titan

LXRX|Lexicon Pharmaceuticals Inc|Price:2.335|Chg%:+0.015 - TradingKey

Lexicon Pharmaceuticals (LXRX) Trading Near $2.34: Support and Resistance Define Near-Term RangeGamma Squeeze - vinanet.vn

Is Lexicon’s Earnings Slide And New Share Shelf Altering The Investment Case For Lexicon Pharmaceuticals (LXRX)? - simplywall.st

Lexicon Pharmaceuticals (STU:LX31) EV-to-OCF : -14.01 (As of Aug. 15, 2026) - GuruFocus

Analysts Have Made A Financial Statement On Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Second-Quarter Report - simplywall.st

Lexicon Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-08-10 - Seeking Alpha

Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat

HC Wainwright Issues Positive Forecast for LXRX Earnings - MarketBeat

Lexicon Pharmaceuticals, Inc. (LXRX) stock price, news, quote and history - Yahoo Finance UK

Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat

Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings - Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Lexicon Pharmaceuticals (LXRX) Stockholders Plan to Sell 1.26M S - GuruFocus

Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highl - GuruFocus

Lexicon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $3.86, Implies 57% Upside - TradingView

Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ... - Yahoo Finance

Lexicon Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat

Lexicon Pharmaceuticals (Nasdaq: LXRX) files shelf to register 1.26M warrant shares - Stock Titan

H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - moomoo.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down on Disappointing Earnings - MarketBeat

FMR LLC (LXRX) discloses 11.7% Lexicon Pharmaceuticals stake in amended 13G - Stock Titan

Is Lexicon Pharmaceuticals (LXRX) Facing Challenges After Q2 Ear - GuruFocus

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Lexicon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss - marketscreener.com

Earnings Flash (LXRX) Lexicon Pharmaceuticals, Inc. Reports Q2 Revenue $692,000, vs. FactSet Est of $4.0M - marketscreener.com

Lexicon: Q2 Earnings Snapshot - marketscreener.com

Lexicon Pharmaceuticals posts Q2 net loss - TradingView

Lexicon Pharmaceuticals Q2 revenue falls to $0.7 million amid clinical updates - Quiver Quantitative

Lexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA Resubmission - Quiver Quantitative

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - The Manila Times

Lexicon Pharma (Nasdaq: LXRX) swings to $31.8M Q2 2026 loss - Stock Titan

BRIEF-Lexicon Pharmaceuticals Q2 EPS USD -0.07 - TradingView

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Zacks Research - MarketBeat

Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView

Lexicon Pharmaceuticals (LXRX) Slips 1.28% as Shares Hold Above Key SupportLiquidity Order Flow - dars.gov.et

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times

Lexicon schedules Aug. 6 call and webcast for Q2 results - Stock Titan

Lexicon Pharmaceuticals (LXRX) to Release Earnings on Wednesday - MarketBeat

Lexicon Pharmaceuticals (LXRX) Rallies 4.93% as Biotech Stock Tests Key Resistance at $2.46Volume Gap - vinanet.vn

Lexicon (LXRX) Completes Patient Randomization in Key Phase 3 Tr - GuruFocus

Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment - marketscreener.com

Lexicon's HCM study spans 20 countries; results anticipated Q1 2027 - Stock Titan

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) - Yahoo Finance Australia

Lexicon Pharmaceuticals Inc (LXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Lexicon Pharmaceuticals Inc (LXRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Lexicon Pharmaceuticals Inc - TradingKey

TradingKey - TradingKey

LXRX|Lexicon Pharmaceuticals Inc|Price:2.355|Chg%:+0.065 - TradingKey

Price to sales forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView

Lexicon Pharmaceuticals Inc (LXRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Lexicon Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:LXRX - TradingView

LXRX|Lexicon Pharmaceuticals Inc|Price:2.290|Chg%:-0.010 - TradingKey

Lexicon Pharmaceuticals Inc (LXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

BNTX

$103.76

0.86%

INSM

$126.29

0.31%

RPRX

$63.96

0.13%

ALNY

$266.11

0.61%

ONC

$358.26

1.22%

RVMD

$210.02

0.40%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters